ZYTIGA® (abiraterone) 250 mg
Product Overview
| Generic Name | ZYTIGA® (abiraterone) 250 mg |
| Brand Name(s) | ZYTIGA® |
| Category | Antineoplastic / Cancer |
| Form | 60 Oral Tablets per bottle |
| Strength | 250 mg |
| Therapeutic Class | Endocrine therapy; androgen biosynthesis inhibitor; CYP17 inhibitor. |
| ATC Code | L02BX03 |
Manufacturing & Regulatory
| Manufacturer | Janssen / Johnson & Johnson / Cipla |
| GMP Compliance | W.H.O. |
| DMF/CEP | Type II: API DMFs |
| COFEPRIS | 010.000.5657.00 |
| Free Sale Certificate | Yes, available as COPP/CPP |
Logistics & Export
| MOQ | 5 bottles |
| Shelf Life | 24 Months |
| Storage | store at 20°C to 25°C, |
| Incoterms | Ex-Works, 30049099 |
| Lead Time | 7 - 10 Business Days |
Documentation Available Upon Request
| Certificate of Analysis (PDF) | Manufacturer provides COA |
| GMP Certificate (PDF) | Yes |
| SDS-Safety Data Sheet (PDF) | Upon Request |
| CTD Summary (PDF) | CTD proprietary; available under commercial agreement/license |
Special Notes
Indications & Usage: Treats prostate cancer advanced metastatic, bottle contains 60 oral tablets